A three-year study of nosocomial infections associated with Pseudomonas aeruginosa.

Journal of Clinical Microbiology
R J Sherertz, F A Sarubbi

Abstract

During a 3-year study period in a university teaching hospital, 417 nosocomial infections associated with Pseudomonas aeruginosa were documented in 321 patients. The overall rate of P. aeruginosa nosocomial infection was 5.3 cases per 1,000 patients. Residence on the surgery or medicine service, advanced patient age, and exposure to the burn, surgery, or medicine intensive care units correlated with higher rates of infection. The most common sites for P. aeruginosa infection were the lower respiratory tract, urinary tract, blood stream, and surgical wounds. Nosocomial P. aeruginosa lower respiratory tract and blood stream infections were significantly associated with exposure to certain intensive care units, whereas P. aeruginosa urinary tract infections more commonly occurred on the neurology and neurosurgery services. Results of live antigen serotyping showed that serotype 6 was most common, followed by serotypes 1 and 11. Serotype 6 correlated with resistance to carbenicillin, gentamicin, and tobramycin, and serotype 11 correlated with resistance to carbenicillin. Two-thirds of the isolates tested were sensitive to carbenicillin, gentamicin, and tobramycin, but 13.2% were resistant to all three of these drugs. P. aeruginosa ...Continue Reading

References

Jun 1, 1977·Journal of Clinical Microbiology·C D BrokoppJ J Farmer
Apr 1, 1976·The American Journal of Medicine·M R Flick, L E Cluff
Aug 1, 1973·The American Journal of Medicine·J E PenningtonP P Carbone
Nov 1, 1974·The Journal of Infectious Diseases·J V Bennett
Nov 1, 1974·The Journal of Infectious Diseases·R S BaltimoreM S Artenstein
Aug 1, 1970·The American Journal of the Medical Sciences·G P Bodey
Aug 1, 1982·Journal of Clinical Microbiology·J J FarmerC D Brokopp
Sep 1, 1982·Journal of Clinical Microbiology·N J LegakisM Papapetropoulou

❮ Previous
Next ❯

Citations

Sep 1, 1992·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C L PohL Tay
Jan 1, 1986·Antonie van Leeuwenhoek·C Cervantes-VegaM G Rodriguez
Dec 1, 1987·European Journal of Epidemiology·D Jurado ChacónR Rodriguez-Contreras Pelayo
Jun 1, 1993·Epidemiology and Infection·G DöringC Wolz
Nov 16, 2010·Journal of Bacteriology·Yongxin JinShouguang Jin
Sep 1, 1996·Annals of Tropical Paediatrics·M K Hendricks, M Senekal
Oct 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I ParaskakiN J Legakis
Dec 17, 2005·Internal Medicine·Takuhiro YoshidaShu-Ichi Ikeda
Jul 1, 1984·Journal of Clinical Microbiology·J A FyfeJ R Govan
Oct 1, 1984·Disease-a-month : DM·H C Neu
Oct 30, 2012·Langmuir : the ACS Journal of Surfaces and Colloids·King Hang Aaron LauPhillip B Messersmith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.